Overview

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

Status:
Terminated

Trial end date:
2014-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess whether maraviroc administered once daily is non-inferior to emtricitabine/tenofovir also administered once daily each in combination with darunavir/ritonavir in the treatment of antiretroviral-naive patients as evaluated at Week 48 of treatment.

Phase:

Phase 3

Details

Lead Sponsor:

ViiV Healthcare

Collaborator:

Pfizer

Treatments:

Darunavir
Emtricitabine
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Maraviroc
Ritonavir
Tenofovir